Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2024, Novartis (NVS) reported revenue of $12.82 billion, up 8.8% over the same period last year. EPS came in at $2.06, compared to $1.74 in the year-ago quarter.The reported revenue represents a surprise of +1.63% over the Zacks Consensus Estimate of $12.62 billion. With the consensus EPS estimate being $1.94, the EPS surprise was +6.19%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Novartis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Hematology- Tasigna- US: $226 million compared to the $218.15 million average estimate based on two analysts. The reported number represents a change of +2.3% year over year. Net sales- Cardiovascular, renal and metabolic- Leqvio- ROW: $97 million versus $99.48 million estimated by two analysts on average. Revenues- Hematology- Promacta/Revolade- US: $306 million versus $285.06 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.6% change. Revenues- Immunology- Cosentyx- US: $993 million versus $819.09 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +38.5% change. Revenues- Solid Tumors- Tafinlar + Mekinist- Total: $534 million versus the three-analyst average estimate of $523.88 million. The reported number represents a year-over-year change of +10.8%. Revenues- Net sales to third parties: $12.82 billion versus $12.51 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.1% change. Revenues- Solid Tumors- Kisqali- Total: $787 million compared to the $795.78 million average estimate based on three analysts. The reported number represents a change of +40% year over year. Revenues- Neuroscience- Gilenya- Total: $130 million versus $130.29 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -51.9% change. Revenues- Immunology- Cosentyx- Total: $1.69 billion compared to the $1.53 billion average estimate based on three analysts. The reported number represents a change of +27.4% year over year. Revenues- Cardiovascular- Entresto- Total: $1.87 billion versus $1.90 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +25.6% change. Revenues- Established Brands- Galvus Group- Total: $159 million versus the three-analyst average estimate of $143.56 million. The reported number represents a year-over-year change of -12.2%. Revenues- Established Brands- Exforge Group- Total: $174 million versus $174.81 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7% change. View all Key Company Metrics for Novartis here>>>Shares of Novartis have returned +0.5% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks